News about "Genentech"

US FDA Grants Priority Review to Genentech?s Enspryng for MOGAD

The US Food and Drug Administration (FDA) has granted priority review to Genentech’s Enspryng for MOGAD after phase 3 METEOROID data showed a 68 percent reduction in relapse risk.

Genentech | 11/09/2026 | By News Bureau

Roche's Genentech Expands US Manufacturing Operations

Roche’s Genentech expands US manufacturing with a new Hillsboro, Oregon facility for assembling injectable medicines and delivery devices.

Genentech | 21/08/2026 | By News Bureau |  105

Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer

Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.

Genentech | 07/07/2026 | By News Bureau |  127

Astex Partners with Genentech on Breast Cancer Therapy Research

Astex has entered an exclusive research and licensing agreement with Genentech for a breast cancer therapy program, with potential deal value exceeding USD 490 million plus tiered royalties.

Genentech | 07/07/2026 | By News Bureau

US FDA Accepts NDA for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer

The US FDA has accepted Genentech’s New Drug Application (NDA) for giredestrant, an investigational oral SERD for ER-positive early-stage breast cancer. Supported by positive phase 3 trial results, giredestrant is the first and only oral SERD to demonstrate efficacy in the curative setting.

Genentech | 03/06/2026 | By News Bureau |  116

Lupus Research Alliance and Genentech Launch Global Research Programme on Immune Reset Therapies for Lupus

The Lupus Research Alliance and Genentech announce inaugural recipients of the Immune Resetting Therapies for Lupus Award to accelerate research into CAR-T cell therapies for severe lupus patients.

Genentech | 28/05/2026 | By News Bureau |  213

Genentech's Gazyva Shows Strong Phase III Results in Primary Membranous Nephropathy

Phase III MAJESTY trial shows Gazyva significantly improves complete remission rates in primary membranous nephropathy, potentially paving the way for the first targeted therapy for the condition.

Genentech | 17/02/2026 | By News Bureau |  254

SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech

SanegeneBio has licensed one of its RNAi programmes to Genentech in a global collaboration valued at up to USD 1.7 billion, including a USD 200 million upfront payment, milestone-based development and commercialisation payments, and tiered royalties. Genentech will oversee worldwide clinical development and commercialisation.

Genentech | 03/02/2026 | By News Bureau |  217

FDA Approves Genentech's Gazyva for Treatment of Lupus Nephritis

The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab), developed by Genentech, for the treatment of adults with lupus nephritis (LN), also known as lupus-related kidney disease.

Genentech | 21/10/2025 | By Dineshwori |  249

Genentech Invests USD 700M to Build First East Coast Manufacturing Facility in North Carolina

The project represents an initial investment of more than USD 700 million and is part of Roche’s broader USD 50 billion commitment to strengthen US manufacturing infrastructure and R&D. Once completed, the site will create over 1,900 jobs.

Genentech | 28/08/2025 | By Darshana |  212